Antion Logo - RGB - Web version-01.png
Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements
March 06, 2024 06:55 ET | ANTION BIOSCIENCES SA
Antion Biosciences release in vivo proof-of-concept data for miCAR7 and milestone achievement for Allogene Therapeutics
Antion Logo - RGB - Web version-01.png
Antion Biosciences Announces Presentation of Two Abstracts from its Multiplex Cell Engineering Platform at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
October 17, 2023 06:55 ET | ANTION BIOSCIENCES SA
Functional demonstration of Antion’s uniquely capable technology to develop allogeneic anti-CD19 CAR T-cells with “tuned” silencing of HLA-I Latest advancements in the application of Antion’s miCAR...
Antion Logo - RGB - Web version-01.png
Antion Announces Granting of Key Technology Patent in the United States
September 06, 2023 09:23 ET | ANTION BIOSCIENCES SA
GENEVA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Antion Biosciences SA (Antion), an innovative developer of cell and gene therapy technologies, is pleased to announce the granting of a significant patent...
Antion Logo - RGB - Web version-01.png
Antion Welcomes John Tchelingerian as Chairman of the Board
August 09, 2023 06:55 ET | ANTION BIOSCIENCES SA
GENEVA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Antion Biosciences SA (Antion) proudly announces the appointment of John Tchelingerian, PhD, a veteran of the biotech industry, as the new Chairman of its...